Accumulating studies have proved that abrogation of VDAC1 expression significantly inhibited tumor growth in cancers [48, 50–54], suggesting that VDAC1 may be a novel therapeutic target [55–58]. The gene discussed is VDAC1; the disease is neoplasm.